By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Peripheral opioid receptor antagonists > Naloxegol > Naloxegol Dosage
Peripheral opioid receptor antagonists
https://themeditary.com/dosage-information/naloxegol-dosage-8780.html

Naloxegol Dosage

Drug Detail:Naloxegol (Naloxegol [ nal-ox-ee-gol ])

Drug Class: Peripheral opioid receptor antagonists

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Constipation - Drug Induced

Opioid-Induced Constipation - Chronic:

Initial dose: 25 mg orally once a day
Maintenance dose: 25 mg orally once a day; dose may be reduced to 12.5 mg orally once a day for patients unable to tolerate higher dose

Comments: Prior to initiation, discontinue all maintenance laxative therapy; laxatives can be used as needed for suboptimal response after 3 days.

Use: For the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Renal Dose Adjustments

  • CrCl less than 60 mL/min: Reduce starting dose to 12.5 mg orally once a day; may increase to 25 mg orally once a day as needed for symptoms, if tolerated.
  • Use caution in patients with renal impairment as there is a potential for markedly increased exposures in some patients with renal impairment.

Liver Dose Adjustments

Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Avoid use

Dose Adjustments

Dose Adjustments due to Drug Interactions:

  • Concomitant use with strong CYP450 3A4 inhibitors is contraindicated.
  • Concomitant use with moderate CYP450 3A4 inhibitors should be avoided; if unavoidable, reduce dose of naloxegol to 12.5 mg orally once a day and monitor for adverse reactions.

  • Discontinue use of this drug if treatment with the opioid pain medication is discontinued.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take on an empty stomach, 1 hour before the first meal of the day or 2 hours after the meal
  • Swallow tablets whole, do not crush or chew
  • If unable to swallow tablets whole, may crush to a powder and mix with 4 ounces of water; drink immediately, then rinse glass with an additional 4 ounces of water and drink again.
  • Avoid grapefruit (juice and fruit) during treatment

NASOGASTRIC (NG) Administration:
  • Flush NG tube with 30 mL of water using a 60 mL syringe
  • Crush tablet and mix with 60 mL of water; draw mixture into 60 mL syringe and administer contents through NG tube
  • Rinse container used to mix crushed tablet with water with an additional 60 mL of water; use all the water to flush the NG tube.

General:
  • If treatment with opioid pain medication is discontinued, this drug should be discontinued.
  • In patients with chronic non-cancer pain, all maintenance laxative therapy should be discontinued prior to initiating therapy; laxatives can be used as needed after 3 days.
  • This drug has been shown to be efficacious in patients who have taken opioids for at least 4 weeks; sustained exposure to opioids prior to starting this drug may increase the patient's sensitivity.

Monitoring:
  • Monitor for the development of severe, persistent, or worsening abdominal pain

Patient advice:
  • If unusually severe, persistent, or worsening abdominal pain develops, promptly seek medical attention.
  • If severe or persistent diarrhea occurs, patients should be advised to stop therapy and consult their healthcare provider.
  • If symptoms of opioid withdrawal such as sweating, chills, anxiety, irritability, and yawning occur, patients should be instructed to let their healthcare provider know.
  • Speak to your physician or health care professional if you become pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

  • Which drugs cause opioid-induced constipation?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by